Literature DB >> 18848731

Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia.

Henry Nasrallah1, Pierluigi Morosini, Dennis D Gagnon.   

Abstract

This report describes the measurement properties of the Personal and Social Performance scale (PSP), a clinician-reported measure of severity of personal and social dysfunction, in an outpatient population with stabilized schizophrenia. Pooled data from two similar antipsychotic clinical studies were analyzed (n=411). The PSP showed good test-retest reliability (intraclass correlation coefficient=0.79). The PSP was more highly correlated with the Strauss-Carpenter Level of Function, an instrument measuring a similar construct, than the Positive and Negative Syndrome Scale, an instrument measuring a different construct. There was a statistically significant difference between mean PSP scores in subjects grouped by their severity rating on the Clinical Global Impression-Severity (CGI-S) (mild or less versus at least moderate), indicating the ability to discriminate between known groups. Effect sizes for mean change in the PSP based on 1-category improvement (0.72) or worsening (-0.88) versus no change in the CGI-S were moderate to large, demonstrating the ability to detect change. Estimates of between-group minimum important difference suggest that a 7-point improvement in the PSP may be clinically meaningful in a clinical trial setting. Initial reliability and validity assessments suggest the PSP may be a useful measure of social functioning in patients with stable schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18848731     DOI: 10.1016/j.psychres.2007.11.012

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  54 in total

1.  An open-label, prospective study to evaluate social function and overall improvement of extended-release paliperidone treatment in Thai schizophrenia patients.

Authors:  Chawanun Charnsil; Salinee Vongpanich
Journal:  Neuropsychiatr Dis Treat       Date:  2013-08-20       Impact factor: 2.570

2.  The interplay among psychopathology, personal resources, context-related factors and real-life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and non-recovered patients.

Authors:  Silvana Galderisi; Paola Rucci; Armida Mucci; Alessandro Rossi; Paola Rocca; Alessandro Bertolino; Eugenio Aguglia; Mario Amore; Antonello Bellomo; Paola Bozzatello; Paola Bucci; Bernardo Carpiniello; Enrico Collantoni; Alessandro Cuomo; Liliana Dell'Osso; Fabio Di Fabio; Massimo di Giannantonio; Dino Gibertoni; Giulia Maria Giordano; Carlo Marchesi; Palmiero Monteleone; Lucio Oldani; Maurizio Pompili; Rita Roncone; Rodolfo Rossi; Alberto Siracusano; Antonio Vita; Patrizia Zeppegno; Mario Maj
Journal:  World Psychiatry       Date:  2020-02       Impact factor: 49.548

3.  Cognitive Behavioral Therapy for Psychosis (CBT-p) Delivered in a Community Mental Health Setting: A Case Comparison of Clients Receiving CBT Informed Strategies by Case Managers Prior to Therapy.

Authors:  Harry J Sivec; Vicki L Montesano; David Skubby; Kristen A Knepp; Mark R Munetz
Journal:  Community Ment Health J       Date:  2015-08-23

4.  Baseline Demographics and Characteristics From a Paliperidone Palmitate Study in Subjects with Recent-Onset Schizophrenia or Schizophreniform Disorder.

Authors:  Brianne Brown; Larry Alphs; Ibrahim Turkoz; Yong Yue
Journal:  Psychopharmacol Bull       Date:  2017-08-01

5.  A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia.

Authors:  Henry A Nasrallah; Srihari Gopal; Cristiana Gassmann-Mayer; Jorge A Quiroz; Pilar Lim; Mariëlle Eerdekens; Eric Yuen; David Hough
Journal:  Neuropsychopharmacology       Date:  2010-06-16       Impact factor: 7.853

6.  Needs, Perceived Support, and Hospital Readmissions in Patients with Severe Mental Illness.

Authors:  Jose Guzman-Parra; Berta Moreno-Küstner; Fabio Rivas; Mercedes Alba-Vallejo; Javier Hernandez-Pedrosa; Fermin Mayoral-Cleries
Journal:  Community Ment Health J       Date:  2017-02-07

7.  A Random Forest Model for Predicting Social Functional Improvement in Chinese Patients with Schizophrenia After 3 Months of Atypical Antipsychotic Monopharmacy: A Cohort Study.

Authors:  Yange Li; Lei Zhang; Yan Zhang; Hui Wen; Jingjing Huang; Yifeng Shen; Huafang Li
Journal:  Neuropsychiatr Dis Treat       Date:  2021-03-19       Impact factor: 2.570

8.  Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis.

Authors:  D J Siskind; M Harris; A Phillipou; V A Morgan; A Waterreus; C Galletly; V J Carr; C Harvey; D Castle
Journal:  Epidemiol Psychiatr Sci       Date:  2016-07-18       Impact factor: 6.892

Review 9.  The impact of newer atypical antipsychotics on patient-reported outcomes in schizophrenia.

Authors:  A George Awad; Lakshmi N P Voruganti
Journal:  CNS Drugs       Date:  2013-08       Impact factor: 5.749

10.  The relationships of personal resources with symptom severity and psychosocial functioning in persons with schizophrenia: results from the Italian Network for Research on Psychoses study.

Authors:  Alessandro Rossi; Silvana Galderisi; Paola Rocca; Alessandro Bertolino; Armida Mucci; Paola Rucci; Dino Gibertoni; Eugenio Aguglia; Mario Amore; Ileana Andriola; Antonello Bellomo; Massimo Biondi; Gaetano Callista; Anna Comparelli; Liliana Dell'Osso; Massimo Di Giannantonio; Andrea Fagiolini; Carlo Marchesi; Palmiero Monteleone; Cristiana Montemagni; Cinzia Niolu; Giuseppe Piegari; Federica Pinna; Rita Roncone; Paolo Stratta; Elena Tenconi; Antonio Vita; Patrizia Zeppegno; Mario Maj
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-07-06       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.